Prevention of rectal transmission of SIV in macaques using FTC with tenofovir: FTC has independent protective effect even as monotherapy

HIV Treat Bull - Vol. 7, No. 5, May 2006

Walid Heneine from CDC Atlanta, presented results showing that adding FTC to tenofovir provided greater protection against SIV infection that standard dose tenofovir. A separate study with FTC monotherapy found an independent protective effect.

Six rhesus macaques were injected subcutaneously with 22 mg TDF and 20 mg FTC per kg once daily, started nine days prior to HIV exposure, and untreated six animals were used as a control group. The FTC dose is comparable to standard human dose, and tenfovir exposure was slightly higher. All animals were exposed rectally with SHIV comparable to viral load levels found in semen during acute HIV infection. Historic data on control macaques using this repeat exposure model shows that 4 virus challenges infect ~75% of the animals.

Of 6 controls, 4 (67%) became infected after 4 challenges (median = 2.5; range = 2 to 4). In contrast, all 6 animals treated with TDF/FTC were fully protected. After 10 additional virus challenges, 1 of 2 remaining controls became infected while all 6 TDF/FTC-treated animals remained uninfected.

The experiment was repeated using FTC monotherapy, with up to 10 HIV exposures, with one animal becoming infected at week 5 and another at week 10. Surprisingly, resistance data on the first animal remained wild-type with no M184V after a further 5 weeks monotherapy.

COMMENT

Studies are clearly required to understand whether a similar level of protection would be provided for adults. In this study the theoretical advantage of dual therapy appeared to result in reduced transmission.

Ref: Heneine W, Garcia-Lerma J, Qari S et al. Prevention of Rectal SHIV Transmission in Macaques by Tenofovir/FTC Combination. 13th CROI. Abstract 32LB.

2008-03-10
IB060705-25

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.